Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi

Trial Profile

Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Isavuconazonium (Primary) ; Isavuconazonium (Primary)
  • Indications Aspergillosis; Blastomycosis; Coccidioidomycosis; Cryptococcosis; Histoplasmosis; Mycoses; Paracoccidioidomycosis
  • Focus Registrational; Therapeutic Use
  • Acronyms VICAL; VITAL
  • Sponsors Astellas Pharma; Basilea Pharmaceutica
  • Most Recent Events

    • 25 Apr 2017 Results analysing economic evaluation of the phase III VITAL study and FungiScope matched case-control analysis, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases.
    • 30 Oct 2016 Results assessing pharmacokinetics in obese versus non-obese patients with fungal infections from SECURE, ACTIVE and VITAL trials (n=218) presented at the IDWeek 2016.
    • 27 Jun 2016 Results published in the Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top